Sign In
Buy AORT
$26.83
-0.84 (-3.04%)
At Close: Jul 31, 2026
Best Momentum Stocks to Buy for January 7th
11:25am, Tuesday, 07'th Jan 2025
NN, VERX and AORT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 7, 2024.
New Strong Buy Stocks for January 7th
08:21am, Tuesday, 07'th Jan 2025
AORT, VERX, NN, IMCR and EVER have been added to the Zacks Rank #1 (Strong Buy) List on January 7, 2024.
US medical device giant Artivion says hackers stole files during cybersecurity incident
10:52am, Monday, 09'th Dec 2024
Artivion, a medical device company that manufactures implantable tissues for cardiac and vascular transplant applications, says its services have been “disrupted” due to a cybersecurity incident.
Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis
08:00am, Monday, 09'th Dec 2024
ATLANTA , Dec. 9, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration
Artivion, Inc. (AORT) Q3 2024 Earnings Call Transcript
12:02pm, Saturday, 09'th Nov 2024
Artivion, Inc. (NYSE:AORT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Ch
Artivion (AORT) Tops Q3 Earnings and Revenue Estimates
07:10pm, Thursday, 07'th Nov 2024
Artivion (AORT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago.
Artivion Reports Third Quarter 2024 Financial Results
04:05pm, Thursday, 07'th Nov 2024
Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP cons
Artivion to Participate in Upcoming Investor Conferences
04:15pm, Tuesday, 05'th Nov 2024
ATLANTA , Nov. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results
04:15pm, Thursday, 24'th Oct 2024
ATLANTA , Oct. 24, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2024 financial result
5-Year Data from the AMDS DARTS Trial Demonstrates Positive Aortic Remodeling with 94% of Patients Free from Unanticipated Reoperation 30-Day Data from the AMDS PERSEVERE Trial Shows Cerebral Malperfu
Artivion, Inc. (AORT) Q2 2024 Earnings Call Transcript
02:45pm, Saturday, 10'th Aug 2024
Artivion, Inc. (NYSE:AORT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief
Artivion (AORT) Surpasses Q2 Earnings and Revenue Estimates
06:50pm, Thursday, 08'th Aug 2024
Artivion (AORT) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.06 per share a year ago.
Artivion Reports Second Quarter 2024 Financial Results
04:05pm, Thursday, 08'th Aug 2024
Second Quarter Highlights: Achieved revenue of $98.0 million in the second quarter of 2024 versus $89.3 million in the second quarter of 2023, an increase of 10% on both a GAAP and constant currency
Artivion to Participate in Upcoming Investor Conferences
04:10pm, Monday, 05'th Aug 2024
ATLANTA , Aug. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming i
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results
04:10pm, Thursday, 25'th Jul 2024
ATLANTA , July 25, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2024 financial resul
